📊 SPRY Key Takeaways
Is ARS Pharmaceuticals, Inc. (SPRY) a Good Investment?
ARS Pharmaceuticals exhibits severe fundamental distress with declining revenue (-5.5% YoY), deep operating losses (net margin -267%), and unsustainable cash burn of -$44.9M annually against only $24.3M cash reserves (approximately 6 months runway). High debt burden (1.57x debt-to-equity) combined with negative operating cash flow leaves limited strategic options for recovery or bridge financing.
ARS Pharmaceuticals, Inc. Key Strengths (SPRY)
- Strong liquidity ratios (current ratio 4.94x, quick ratio 4.30x) provide near-term operational flexibility
- Asset base of $287.6M offers collateral and restructuring value
- As early-stage biotech/pharma, may have pipeline assets with development optionality
SPRY Stock Risks: ARS Pharmaceuticals, Inc. Investment Risks
- Critical cash runway: $24.3M cash with -$44.9M annual operating burn implies 6-month solvency window requiring immediate financing
- Structural unprofitability: operating expenses 365% of revenue with no demonstrated path to profitability
- Deteriorating business fundamentals: declining revenue combined with expanding losses indicates competitive/operational challenges
- Elevated leverage: 1.57x debt-to-equity ratio constrains refinancing options and increases bankruptcy risk
- No insider accumulation activity (0 Form 4 filings in 90 days) suggests management lacks confidence
Key Metrics to Watch
- Monthly cash burn rate and months of runway remaining
- Revenue stabilization/inflection point
- Operating expense reduction progress and pathway to cash flow breakeven
- Pipeline milestone achievements and regulatory approvals
- Debt covenant compliance and refinancing capacity
ARS Pharmaceuticals, Inc. (SPRY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.94x current ratio provides a solid financial cushion.
SPRY Profit Margin, ROE & Profitability Analysis
SPRY vs Healthcare Sector: How ARS Pharmaceuticals, Inc. Compares
How ARS Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ARS Pharmaceuticals, Inc. Stock Overvalued? SPRY Valuation Analysis 2026
Based on fundamental analysis, ARS Pharmaceuticals, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ARS Pharmaceuticals, Inc. Balance Sheet: SPRY Debt, Cash & Liquidity
SPRY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ARS Pharmaceuticals, Inc.'s revenue has grown significantly by 1,519% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.08 reflects profitable operations.
SPRY Revenue Growth, EPS Growth & YoY Performance
SPRY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.0M | -$33.9M | $-0.35 |
| Q3 2025 | $2.1M | -$19.1M | $-0.20 |
| Q2 2025 | $500.0K | -$12.5M | $-0.13 |
| Q1 2025 | N/A | -$10.3M | $-0.11 |
| Q3 2024 | N/A | -$14.9M | $-0.16 |
| Q2 2024 | $10.0K | -$12.5M | $-0.13 |
| Q1 2024 | N/A | -$10.3M | $-0.11 |
| Q3 2023 | N/A | -$6.6M | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ARS Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
SPRY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ARS Pharmaceuticals, Inc. (CIK: 0001671858)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SPRY
What is the AI rating for SPRY?
ARS Pharmaceuticals, Inc. (SPRY) has an AI grade of D with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SPRY's key strengths?
Claude: Strong liquidity ratios (current ratio 4.94x, quick ratio 4.30x) provide near-term operational flexibility. Asset base of $287.6M offers collateral and restructuring value.
What are the risks of investing in SPRY?
Claude: Critical cash runway: $24.3M cash with -$44.9M annual operating burn implies 6-month solvency window requiring immediate financing. Structural unprofitability: operating expenses 365% of revenue with no demonstrated path to profitability.
What is SPRY's revenue and growth?
ARS Pharmaceuticals, Inc. reported revenue of $22.7M.
Does SPRY pay dividends?
ARS Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find SPRY SEC filings?
Official SEC filings for ARS Pharmaceuticals, Inc. (CIK: 0001671858) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SPRY's EPS?
ARS Pharmaceuticals, Inc. has a diluted EPS of $-0.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SPRY's fundamental grade?
Based on our AI fundamental analysis in June 2026, ARS Pharmaceuticals, Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SPRY stock overvalued or undervalued?
Valuation metrics for SPRY: ROE of -98.9% (sector avg: 15%), net margin of -267.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SPRY's AI grade for 2026?
Our dual AI analysis gives ARS Pharmaceuticals, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SPRY's free cash flow?
ARS Pharmaceuticals, Inc.'s operating cash flow is $-44.9M, with capital expenditures of $0.0. FCF margin is -198.2%.
How does SPRY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -267.3% (avg: 12%), ROE -98.9% (avg: 15%), current ratio 4.94 (avg: 2).
Is ARS Pharmaceuticals, Inc. carrying too much debt?
SPRY has a debt-to-equity ratio of 1.57x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 4.94 suggests adequate short-term liquidity.